MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.2007.12.0782

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2007

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Cannistra Stephen A, Matulonis Ursula A, Penson Richard T, Hambleton Julie, Dupont Jakob, Mackey Howard, Douglas Jeffrey, Burger Robert A, Armstrong Deborah, Wenham Robert, McGuire William

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

PURPOSE: We evaluated the efficacy and safety of bevacizumab in patients with platinum-resistant epithelial ovarian carcinoma (EOC) or peritoneal serous carcinoma (PSC) who had experienced disease progression during, or within 3 months of discontinuing, topotecan or liposomal doxorubicin.

PATIENTS AND

METHODS

No more than three prior treatment regimens were allowed. Patients received single-agent bevacizumab 15 mg/kg intravenously every 3 weeks. Response was assessed by computed tomography (CT) scan every 6 weeks using Response Evaluation Criteria in Solid Tumors (RECIST).

RESULTS

Of 44 patients treated, 83.7% were primarily platinum resistant, 59.1% had received liposomal doxorubicin, 25% topotecan, 15.9% both agents, and 47.7% had received three prior chemotherapy regimens. A median of five (range, two to 16) bevacizumab doses were administered. Partial responses were observed in seven patients (15.9%). Median progression-free survival was 4.4 months (95% CI, 3.1 to 5.5 months), with a median survival duration of 10.7 months at study termination. Bevacizumab-associated grade 3 to 4 events included hypertension (9.1%), proteinuria (15.9%), bleeding (2.3%), and wound-healing complications (2.3%). The incidence of GI perforation (GIP; 11.4%) was higher than reported in bevacizumab trials of other tumor types. GIP occurred in 23.8% of patients receiving three prior chemotherapy regimens, compared with 0% of patients receiving two prior chemotherapy regimens (P < .01). A trend toward higher risk of GIP was observed for patients with bowel wall thickening or bowel obstruction on CT scan. Arterial thromboembolic events occurred in three patients (6.8%). Three deaths were related to bevacizumab treatment.

CONCLUSION

Bevacizumab has single-agent activity in patients with platinum-resistant EOC or PSC. A higher than expected incidence of GIP was noted in these heavily pretreated patients.

Для цитирования: Cannistra Stephen A, Matulonis Ursula A, Penson Richard T, Hambleton Julie, Dupont Jakob, Mackey Howard, Douglas Jeffrey, Burger Robert A, Armstrong Deborah, Wenham Robert, McGuire William. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. DOI: 10.1200/jco.2007.12.0782.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.